EGA
RIGL icon

Eagle Global Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Eagle Global Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,982
Closed -$41K – 388
2016
Q1 		$41K Hold
1,982
– – ﹤0.01% 365
2015
Q4 		$60K Buy
+1,982
New +$60.1K ﹤0.01% 361

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eagle Global Advisors's RIGL Position: Q2 2016 in Review

Eagle Global Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2016, closing a stake of 1,982 shares — an estimated $41K sold.

Eagle Global Advisors first reported a position in RIGL in Q4 2015 and held it in 2 quarters. The position peaked at $60K in Q4 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q2 2016.

  • Eagle Global Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 1,982 Rigel Pharmaceuticals shares in Q2 2016, an estimated $41K.
  • Eagle Global Advisors first reported a position in Rigel Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Eagle Global Advisors's Rigel Pharmaceuticals position peaked at $60K in Q4 2015.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2016.

Based on Eagle Global Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.